Design and Structure−Activity Relationships of Potent and Selective Inhibitors of Blood Coagulation Factor Xa

1999 ◽  
Vol 42 (18) ◽  
pp. 3557-3571 ◽  
Author(s):  
William R. Ewing ◽  
Michael R. Becker ◽  
Vincent E. Manetta ◽  
Roderick S. Davis ◽  
Henry W. Pauls ◽  
...  
1998 ◽  
Vol 41 (4) ◽  
pp. 437-450 ◽  
Author(s):  
Scott I. Klein ◽  
Mark Czekaj ◽  
Charles J. Gardner ◽  
Kevin R. Guertin ◽  
Daniel L. Cheney ◽  
...  

1996 ◽  
Vol 83 (2) ◽  
pp. 117-126 ◽  
Author(s):  
Pancras C Wong ◽  
Earl J Crain ◽  
Oliver Nguan ◽  
Carol A Watson ◽  
Adrienne Racanelli

2011 ◽  
Vol 42 (3) ◽  
pp. 180-191 ◽  
Author(s):  
Gianfranco Lopopolo ◽  
Filomena Fiorella ◽  
Modesto de Candia ◽  
Orazio Nicolotti ◽  
Sophie Martel ◽  
...  

2004 ◽  
Vol 47 (16) ◽  
pp. 4089-4099 ◽  
Author(s):  
J. Adam Willardsen ◽  
Danette A. Dudley ◽  
Wayne L. Cody ◽  
Liguo Chi ◽  
Thomas B. McClanahan ◽  
...  

2021 ◽  
Vol 22 (2) ◽  
pp. 880
Author(s):  
Thomas Schmitz ◽  
Ajay Abisheck Paul George ◽  
Britta Nubbemeyer ◽  
Charlotte A. Bäuml ◽  
Torsten Steinmetzer ◽  
...  

The saliva of blood-sucking leeches contains a plethora of anticoagulant substances. One of these compounds derived from Haementeria ghilianii, the 66mer three-disulfide-bonded peptide tridegin, specifically inhibits the blood coagulation factor FXIIIa. Tridegin represents a potential tool for antithrombotic and thrombolytic therapy. We recently synthesized two-disulfide-bonded tridegin variants, which retained their inhibitory potential. For further lead optimization, however, structure information is required. We thus analyzed the structure of a two-disulfide-bonded tridegin isomer by solution 2D NMR spectroscopy in a combinatory approach with subsequent MD simulations. The isomer was studied using two fragments, i.e., the disulfide-bonded N-terminal (Lys1–Cys37) and the flexible C-terminal part (Arg38–Glu66), which allowed for a simplified, label-free NMR-structure elucidation of the 66mer peptide. The structural information was subsequently used in molecular modeling and docking studies to provide insights into the structure–activity relationships. The present study will prospectively support the development of anticoagulant-therapy-relevant compounds targeting FXIIIa.


Biochemistry ◽  
1992 ◽  
Vol 31 (23) ◽  
pp. 5374-5380 ◽  
Author(s):  
Susan P. Jordan ◽  
Shi Shan Mao ◽  
Sidney D. Lewis ◽  
Jules A. Shafer

2005 ◽  
Vol 93 (01) ◽  
pp. 40-47 ◽  
Author(s):  
Md. Abu Reza ◽  
Sanjay Swarup ◽  
Manjunatha Kini

SummaryIt is uncommon for similar pathways/systems to be involved in highly divergent functions within single organisms. Earlier, we have shown that trocarin D, a venom prothrombin activator, from the Australian rough-scaled snake Tropidechis carinatus, is structurally and functionally similar to the blood coagulation factor Xa (FXa). The presence of a haemostatic system in these snakes implies that they have two parallel prothrombin activating systems: one in the plasma, that participates in the life saving process of blood clotting and the other in their venom, where it acts as a toxin. Here, we report the complete cDNA sequence encoding the blood coagulation factor X (FX) from the liver of T. carinatus. Deduced T. carinatus FX sequence shows ~80% identity with trocarin D but ~50% identity with the mammalian FX. Our present study confirms the presence of two separate genes – one each for FX and trocarin D, that code for similar proteins in T. carinatus snake. These two genes have different expression sites and divergent uses suggesting that snake venom prothrombin activators have probably evolved by the duplication of the liver FX gene and subsequently marked for tissue-specific expression in the venom gland.


ChemInform ◽  
2010 ◽  
Vol 25 (33) ◽  
pp. no-no
Author(s):  
T. NAGAHARA ◽  
Y. YOKOYAMA ◽  
K. INAMURA ◽  
S. KATAKURA ◽  
S. KOMORIYA ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document